Systemic lupus erythematosus in children and young people
Abstract Purpose of Review Juvenile-onset systemic lupus erythematosus ((j) SLE) is an
autoimmune/inflammatory disease that results in significant damage and disability. When …
autoimmune/inflammatory disease that results in significant damage and disability. When …
An update on the management of childhood-onset systemic lupus erythematosus
Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic,
inflammatory, heterogeneous autoimmune condition. This disease is characterized by …
inflammatory, heterogeneous autoimmune condition. This disease is characterized by …
10 Years of belimumab experience: What have we learnt?
RA Levy, T Gonzalez-Rivera, M Khamashta, NL Fox… - Lupus, 2021 - journals.sagepub.com
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting both adults and children. Belimumab is the only biologic approved for SLE, and the …
affecting both adults and children. Belimumab is the only biologic approved for SLE, and the …
Treatment of lupus nephritis: consensus, evidence and perspectives
Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …
Advances in the pathogenesis and treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant
disease, characterized by multiple organ damage, that in its most severe forms can be life …
disease, characterized by multiple organ damage, that in its most severe forms can be life …
The lupus nephritis management renaissance
JM Mejia-Vilet, A Malvar, A Arazi, BH Rovin - Kidney International, 2022 - Elsevier
Over the past year, and for the first time ever, the US Food and Drug Administration
approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus …
approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus …
New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review
R Felten, M Scherlinger, P Mertz, F Chasset, L Arnaud - Joint Bone Spine, 2023 - Elsevier
Introduction Despite available therapies, persistently active and corticosteroid-dependent
Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. The …
Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. The …
Emerging B-cell therapies in systemic lupus erythematosus
A Bag-Ozbek, JS Hui-Yuen - Therapeutics and clinical risk …, 2021 - Taylor & Francis
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of
unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising …
unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising …
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration | Nature Reviews
Rheumatology Skip to main content Thank you for visiting nature.com. You are using a browser …
Rheumatology Skip to main content Thank you for visiting nature.com. You are using a browser …
Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an …
Objectives Application of 'treat-to-target'(T2T) in childhood-onset systemic lupus
erythematosus (cSLE) may improve care and health outcomes. This initiative aimed to …
erythematosus (cSLE) may improve care and health outcomes. This initiative aimed to …